Resectable Pancreatic Cancer Clinical Trial
Official title:
Clinical Study of a Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
This research study is evaluating a new type of pancreatic cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of resectable pancreatic cancer, so as to provide a new personalized therapeutic strategy. It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05209074 -
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
| Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
| Recruiting |
NCT02243007 -
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05679050 -
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Withdrawn |
NCT01694589 -
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
|
Phase 0 | |
| Active, not recruiting |
NCT03138720 -
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01298011 -
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT06363084 -
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
|
||
| Completed |
NCT01992705 -
Borderline Pancreas Study: FOLFIRINOX +SBRT
|
Early Phase 1 | |
| Recruiting |
NCT05624918 -
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT02047513 -
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT02115022 -
EUS vs. MDCT in Pancreatic Malignancy
|
||
| Recruiting |
NCT03492671 -
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT05546411 -
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06172036 -
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
|
Phase 2 | |
| Recruiting |
NCT05788744 -
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04737551 -
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
|
||
| Recruiting |
NCT03822936 -
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03435536 -
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
|
N/A |